← FDA ENFORCEMENT
D-0044-2025Class II

Cipla USA, Inc.

Recalling firm
Cipla USA, Inc.
Product type
Drug
Status
Ongoing
Report date
2024-11-20
Distribution
USA nationwide.
Firm state
NJ
Product quantity
N/A
Initiated by
Voluntary: Firm initiated
Reason for recall

Failed Tablet/Capsule Specifications: Complaints received of crushed and broken tablets.

Product description

Lanthanum Carbonate Chewable Tablets, 1000mg, 10-count bottle, Rx only, Manufactured for Exelan Pharmaceuticals, NDC 76282-0478-90

Code / lot info

Lot# NB240873, Exp 03/31/2026

Data: U.S. FDA openFDA enforcement API. Recall details are as reported by the FDA. The quality-domain mapping and severity are a SPEQ editorial interpretation of the recall reason, not an official FDA classification.